drugset / Trial / NCT05675319
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
Phase 3
Terminated
28 enrolled
University Medical Center Hamburg-Eppendorf
Gemeinsamer Bundesaussschuss · collabStaburo GmbH · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Allogeneic stem cell (allo SCT) transplantation for multiple myeloma is a potential curative treatment, but is associated with morbidity and treatment related mortality. Approved drug combinations or another autologous stem cell transplantation (auto-SCT) can be used for relapsed patients resulting in a median progression free survival up to 2-3 years. In the current trial after first-line treatment relapsed or progressed myeloma patients with an HLA compatible donor will be randomized after 3 cycles of salvage therapy to allogeneic stem cell transplantation or to continuous conventional salvage therapy.
Timeline
- Start
- 2023-03-03
- Primary completion
- 2025-03-14
- Completion
- 2025-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogeneic Stem Cells | Cell therapy | — | — |
| Comparator | Bortezomib | Small molecule | — | — |
| Comparator | Carfilzomib | Other / unclassified | — | — |
| Comparator | Daratumumab | Monoclonal antibody | — | — |
| Comparator | Dexamethasone | Small molecule | — | — |
| Comparator | Elotuzumab | Monoclonal antibody | — | — |
| Comparator | Isatuximab | Monoclonal antibody | — | — |
| Comparator | Ixazomib | Unknown | — | — |
| Comparator | Lenalidomide | Other / unclassified | — | — |
| Comparator | Pomalidomide | Other / unclassified | — | — |
| Comparator | Selinexor | Other / unclassified | — | — |
| Comparator | Autologous Stem Cells | Cell therapy | — | — |